P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.

Detalles Bibliográficos
Autores principales: Kersting, Sabina, Levin, Mark-David, Dubois, Julie, van Norden, Yvette, Dobber, Johan, Jauw, Yvonne, van der Kevie-Kersemaekers, Anne-Marie, Mellink, Clemens, Da Cunha-Bang, Caspar, Van Desr Burg, Leonie, Te Raa, Doreen, de Boer, Fransien, Droogendijk, Jolanda, Idink, Cecile, De Heer, Koen, Nijziel, Marten, Tick, Lidwine, Ludwig, Inge, Silbermann, Mathijs, Beeker, Aart, Bellido, Mar, Evers, Ludo, Zwezerijnen, Gerben, Zijlstra, Josée, Kap, Marcel, Niemann, Carsten, Kater, Arnon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429648/
http://dx.doi.org/10.1097/01.HS9.0000969380.79786.1a
_version_ 1785090766590181376
author Kersting, Sabina
Levin, Mark-David
Dubois, Julie
van Norden, Yvette
Dobber, Johan
Jauw, Yvonne
van der Kevie-Kersemaekers, Anne-Marie
Mellink, Clemens
Da Cunha-Bang, Caspar
Van Desr Burg, Leonie
Te Raa, Doreen
de Boer, Fransien
Droogendijk, Jolanda
Idink, Cecile
De Heer, Koen
Nijziel, Marten
Tick, Lidwine
Ludwig, Inge
Silbermann, Mathijs
Beeker, Aart
Bellido, Mar
Evers, Ludo
Zwezerijnen, Gerben
Zijlstra, Josée
Kap, Marcel
Niemann, Carsten
Kater, Arnon
author_facet Kersting, Sabina
Levin, Mark-David
Dubois, Julie
van Norden, Yvette
Dobber, Johan
Jauw, Yvonne
van der Kevie-Kersemaekers, Anne-Marie
Mellink, Clemens
Da Cunha-Bang, Caspar
Van Desr Burg, Leonie
Te Raa, Doreen
de Boer, Fransien
Droogendijk, Jolanda
Idink, Cecile
De Heer, Koen
Nijziel, Marten
Tick, Lidwine
Ludwig, Inge
Silbermann, Mathijs
Beeker, Aart
Bellido, Mar
Evers, Ludo
Zwezerijnen, Gerben
Zijlstra, Josée
Kap, Marcel
Niemann, Carsten
Kater, Arnon
author_sort Kersting, Sabina
collection PubMed
description
format Online
Article
Text
id pubmed-10429648
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104296482023-08-17 P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL. Kersting, Sabina Levin, Mark-David Dubois, Julie van Norden, Yvette Dobber, Johan Jauw, Yvonne van der Kevie-Kersemaekers, Anne-Marie Mellink, Clemens Da Cunha-Bang, Caspar Van Desr Burg, Leonie Te Raa, Doreen de Boer, Fransien Droogendijk, Jolanda Idink, Cecile De Heer, Koen Nijziel, Marten Tick, Lidwine Ludwig, Inge Silbermann, Mathijs Beeker, Aart Bellido, Mar Evers, Ludo Zwezerijnen, Gerben Zijlstra, Josée Kap, Marcel Niemann, Carsten Kater, Arnon Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429648/ http://dx.doi.org/10.1097/01.HS9.0000969380.79786.1a Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Kersting, Sabina
Levin, Mark-David
Dubois, Julie
van Norden, Yvette
Dobber, Johan
Jauw, Yvonne
van der Kevie-Kersemaekers, Anne-Marie
Mellink, Clemens
Da Cunha-Bang, Caspar
Van Desr Burg, Leonie
Te Raa, Doreen
de Boer, Fransien
Droogendijk, Jolanda
Idink, Cecile
De Heer, Koen
Nijziel, Marten
Tick, Lidwine
Ludwig, Inge
Silbermann, Mathijs
Beeker, Aart
Bellido, Mar
Evers, Ludo
Zwezerijnen, Gerben
Zijlstra, Josée
Kap, Marcel
Niemann, Carsten
Kater, Arnon
P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.
title P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.
title_full P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.
title_fullStr P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.
title_full_unstemmed P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.
title_short P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.
title_sort p619: tracking disease parameters by mrd, ct and pet in first line cll patients treated with fixed duration ibrutinib-venetoclax; interim analysis of the first 30 patients in hovon 158/next step trial.
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429648/
http://dx.doi.org/10.1097/01.HS9.0000969380.79786.1a
work_keys_str_mv AT kerstingsabina p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT levinmarkdavid p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT duboisjulie p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT vannordenyvette p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT dobberjohan p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT jauwyvonne p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT vanderkeviekersemaekersannemarie p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT mellinkclemens p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT dacunhabangcaspar p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT vandesrburgleonie p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT teraadoreen p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT deboerfransien p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT droogendijkjolanda p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT idinkcecile p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT deheerkoen p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT nijzielmarten p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT ticklidwine p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT ludwiginge p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT silbermannmathijs p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT beekeraart p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT bellidomar p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT eversludo p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT zwezerijnengerben p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT zijlstrajosee p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT kapmarcel p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT niemanncarsten p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial
AT katerarnon p619trackingdiseaseparametersbymrdctandpetinfirstlinecllpatientstreatedwithfixeddurationibrutinibvenetoclaxinterimanalysisofthefirst30patientsinhovon158nextsteptrial

Ejemplares similares